Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference
So I would say, [00:33:00] um, it's exciting
In some cases, in-office procedures may combine copper peptides with soft tissue augmentation techniques, such as dermal fillers, to further enhance skin rejuvenation and volume restoration
In contrast, brand-name GLP-1 medications underwent clinical trials involving 10,000 or more patients before obtaining FDA approval
Kawakami, Y., Tanda, M., Adachi, S
International recommendations for the Management of Adults Treated with ketogenic diet therapies
